MIRA secures worldwide exclusive rights to MIRA-55 and SKNY-1 via amended license

MIRA PHARMACEUTICALS, INC.

Amended license with MIRALOGX LLC grants MIRA global exclusive rights to develop, commercialize, sublicense, and enforce IP for MIRA-55 and SKNY-1.
Core economic terms from prior license arrangements remain materially unchanged; no upfront or milestone payments disclosed.
MIRA CEO says the company now controls worldwide rights across entire pipeline: Ketamir-2, MIRA-55, and SKNY-1.
MIRA-55 targets chronic inflammatory pain; SKNY-1 targets obesity and addiction-related disorders—both investigational.
Agreement consolidates IP portfolio and enhances flexibility for future licensing and partnership opportunities.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MIRA PHARMACEUTICALS, INC. amended Amended and Restated Exclusive License Agreement with MIRALOGX LLC (effective 2026-06-03).

Action: amendment
Agreement: license
Counterparty: MIRALOGX LLC
Effective: 2026-06-03

Exact text from the filing

On June 3, 2026, MIRA Pharmaceuticals, Inc. (the "Company") entered into an Amended and Restated Exclusive License Agreement (the "License Agreement") with MIRALOGX LLC ("Miralogx").

View on SEC.gov

802 material agreements filed in the last 30 days. Browse all material agreements →

MIRA PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-26-027202

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.